Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | CPN1 | P15169 | 2/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.44 |
| ▸ | EED | O75530 | 4/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8576163 | 1.00 | F2 (0.48) | F2CPN1CPB2EEDNOS2 | |
| SCHEMBL6275890 | 0.87 | — | — | |
| SCHEMBL3123799 | 0.79 | ALDH1A1 (0.36) | CPN1CPB2 | |
| SCHEMBL9147164 | 0.77 | CA12 (0.52) | F2CPN1CPB2EED | |
| SCHEMBL9059444 | 0.77 | CA12 (0.52) | F2CPN1CPB2EED | |
| SCHEMBL9387897 | 0.77 | CA12 (0.52) | F2CPN1CPB2EED | |
| SCHEMBL4550909 | 0.75 | ALDH1A1 (0.50) | F2CPN1CPB2EED | |
| SCHEMBL8574653 | 0.75 | ALDH1A1 (0.50) | F2CPN1CPB2EED | |
| SCHEMBL8574654 | 0.75 | ALDH1A1 (0.50) | F2CPN1CPB2EED | |
| Hydrochloric Acid SCHEMBL2722390 | 0.73 | ALDH1A1 (0.49) | F2CPN1CPB2EED |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855726-B1 | Quinolones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-15 | — | — | US | claimed |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | claimed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | claimed |
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | DUDLEY DANETTE ANDREA (US) | 2002-07-04 | — | — | US | claimed |
| US-6916805-B2 | Quinoxalinones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-07-12 | — | — | US | disclosed |
| US-6855726-B1 | Quinolones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-15 | — | — | US | disclosed |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | disclosed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | disclosed |
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | DUDLEY DANETTE ANDREA (US) | 2002-07-04 | — | — | US | disclosed |
| US-6410536-B1 | ANTICOAGULANTS | WARNER-LAMBERT COMPANY | 2002-06-25 | — | — | US | disclosed |
| EP-1091955-A1 | QUINOLONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-1999050263-A1 | QUINOLONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5763436-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | HABP2, SERPINB1, PRSS1 | F2 11/4885CPN1 219/4885CPB2 71/4885 |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | HABP2, SPINT2, SERPINB1 | F2 25/4885CPN1 797/4885CPB2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.